

A DNA insulator prevents repression of a targeted X-linked transgene but not its random or imprinted X inactivation

Dominic Ciavatta*[†], Sundeep Kalantry^{†*}, Terry Magnuson^{†*§}, and Oliver Smithies*[¶]

Departments of *Pathology and Laboratory Medicine and [†]Genetics, [§]Curriculum in Genetics and Molecular Biology, and [¶]Carolina Center for Genome Sciences, University of North Carolina, Chapel Hill, NC 27599

Contributed by Oliver Smithies, May 8, 2006

Some genes on the inactive X chromosome escape silencing. One possible escape mechanism is that heterochromatinization during X inactivation can be blocked by boundary elements. DNA insulators are candidates for blocking because they shield genes from influences of their chromosomal environment. To test whether DNA insulators can act as boundaries on the X chromosome, we inserted into the mouse X-linked *Hprt* locus a GFP transgene flanked with zero, one, or two copies of a prototypic vertebrate insulator from the chicken β -globin locus, chicken hypersensitive site 4, which contains CCCTC binding factor binding sites. On the active X chromosome the insulators blocked repression of the transgene, which commences during early development and persists in adults, in a copy number-dependent manner. CpG methylation of the transgene correlated inversely with expression, but the insulators on the active X chromosome were not methylated. On the inactive X chromosome, insulators did not block random or imprinted X inactivation of the transgene, and both the insulator and transgene were almost completely methylated. Thus, the chicken hypersensitive site 4 DNA insulator is sufficient to protect an X-linked gene from repression during development but not from X inactivation.

CCCTC binding factor

Eukaryotic genomes contain interspersed domains of transcriptionally active euchromatin and inactive heterochromatin. Heterochromatin can encroach into transcriptionally active euchromatin and silence adjoining genes, as illustrated by position effect variegation in *Drosophila* (1, 2). Maintaining these chromosomal domains and preventing the spread of heterochromatin implies the existence of boundary elements that act as barriers (3). One class of boundary element candidates consists of DNA insulators because they can block the positive effects of an adjacent enhancer and protect a gene from negative position effects (4, 5).

One of the best-characterized vertebrate DNA insulators is from the chicken β -globin locus. In chicken erythrocytes, DNaseI hypersensitive site 4 upstream of the β -globin locus marks the transition between a euchromatic region that contains the β -globin genes and upstream heterochromatin (6, 7). Chicken hypersensitive site 4 (cHS4), a 1.2-kb fragment that encompasses hypersensitive site 4, has both insulator properties: it can block an enhancer in an enhancer blocking assay, and it has barrier activity in a position effect assay (8). A binding site for the transcription factor CTCF (CCCTC binding factor) within cHS4 is necessary and sufficient for its enhancer blocking activity, but is not necessary for its barrier function (9, 10). Flanking copies of cHS4 without the CTCF binding site can still protect randomly integrated transgenes from position effects. In a position effect assay the cHS4 insulator itself and transgenes flanked with it are associated with acetylated histones, histone H3 methylated at lysine 4, and reduced CpG methylation relative to the methylation of uninsulated transgenes (11–13).

A specialized form of heterochromatinization occurs in mammals during X inactivation and results in one of the two X chromosomes in female somatic cells becoming largely transcriptionally inactive (14–16). The silencing of genes on the inactive X chromosome (Xi) is patchy. Ten to 20% of the genes on the human Xi escape inactivation; however, only seven genes on the mouse Xi are known to escape inactivation (17, 18). In humans at least, this escape appears to operate at the level of chromosomal domains possibly demarcated by boundary elements (19, 20). The role for chromosomal domains in escape from X inactivation is supported by the demonstration that a 17-kb chicken transferrin gene randomly integrated as multiple copies on the X chromosome is expressed whether the transgene is on the Xi or the active X chromosome (Xa) (21). However, in two separate transgenic studies, neither the human β -globin locus control region, nor a functional DNA fragment containing matrix attachment regions, resisted silencing on the Xi (22, 23), indicating that these boundary elements are not sufficient to form escape domains on the Xi. A recent report (24) characterized a DNA fragment with insulator properties and CTCF binding sites at the 5' end of three X-linked genes (mouse *Jarid1c* and *Eif2s3x* and human *EIF2S3*) that escape inactivation although they are adjacent to genes that are inactivated, and suggested that CTCF may play a role in maintaining escape domains.

The experiments we describe here show that copies of the cHS4 DNA insulator, which contains a CTCF binding site, flanking a transgene inserted adjacent to the X-linked *Hprt* gene, block in a copy number-dependent manner the partial repression of the transgene that occurs during development and persists in adults. However, random and imprinted X inactivation of the transgene are not blocked by cHS4.

Results and Discussion

Transgenes Were Targeted in Mouse ES Cells to *Hprt* Locus. We chose the hypersensitive site 4 from the chicken β -globin locus, a well characterized vertebrate DNA insulator with a CTCF binding site, to test the effects of flanking insulators on an X-linked transgene. To monitor X inactivation, we used a GFP gene with a nuclear localization signal (GFPn) driven by a ubiquitously active 1.3-kb human β -actin promoter (25). This reporter transgene, flanked with zero, one, or two copies of the 1.2-kb cHS4 insulator sequence (8) (Fig. 1A), was inserted into the X-linked *Hprt* locus of mouse ES cells by using the single-copy chosen site integration method described by Bronson *et al.* (26) (Fig. 1B). It

Conflict of interest statement: No conflicts declared.

Freely available online through the PNAS open access option.

Abbreviations: cHS4, chicken hypersensitive site 4; CTCF, CCCTC binding factor; Xi, inactive X chromosome; Xa, active X chromosome; Xp, paternal X chromosome; Xm, maternal X chromosome; GFPn, GFP gene with a nuclear localization signal; emb, embryonic ectoderm.

[¶]To whom correspondence should be addressed. E-mail: jenny.langenbach@med.unc.edu.

© 2006 by The National Academy of Sciences of the USA





Fig. 1. Transgenic constructs and targeting scheme to insert transgenes into the X-linked *Hprt* locus. (A) The reporter gene (large solid black rectangle) encodes a GFPn. The GFPn gene is driven by a 1.3-kb human β -actin promoter (hatched box); the small solid black rectangle is the first exon of β -actin. Open boxes labeled *Ins* represent the 1.2-kb insulator from the chicken β -globin locus (*cHS4*). (B) (Top) The untargeted *Hprt* locus in the ES cell line (E14Tg2a). The dashed line within parentheses represents the \approx 50-kb deletion that removes the *Hprt* promoter and exons 1 and 2. (Middle) The targeting construct. (Bottom) The *Hprt* locus after homologous recombination. The small black bar shows the location of the probe used for Southern blotting. (C) (Left) The Southern blot obtained when the ES cell DNA was digested with BamHI. The *Hprt* locus in untargeted, WT ES cells gave a 9.2-kb BamHI fragment. Targeted ES cells with the GFPn, I-GFPn-I, or II-GFPn-II transgene gave 9.4-, 10.6-, and 11.8-kb BamHI fragments, respectively. (Right) The Southern blot obtained when the ES cell DNA was digested with PstI. The *Hprt* locus in untargeted, WT ES cells gave a 8.5-kb PstI fragment. The targeted ES cells gave a 7.7-kb PstI fragment with all three transgenes. Ps, PstI; B, BamHI; Phum, human *HPRT* promoter.

was advantageous to insert the reporter transgene into the X-linked *Hprt* locus because we could measure the effect an insulator has on expression when the X chromosome is transcriptionally active or inactive. Southern blot analyses confirmed that the transgenes were integrated as single copies in targeted ES cells (Fig. 1C).

***cHS4* DNA Insulators Affect Changes in Expression During Early Development.** Our first experiments determined the effects of flanking DNA insulators on expression of the GFPn transgene during early development when the transgene is on an Xa. We performed FACS analysis on undifferentiated and differentiated ES cells to measure GFP fluorescence. Fig. 2A shows that the level of fluorescence was the same in undifferentiated male ES cells with zero, one, or two copies of *cHS4* flanking the GFPn transgene. When ES cells were differentiated *in vitro* to embryoid bodies, the level of GFP fluorescence differed markedly among the three cell lines. Expression of the GFPn transgene was highest when flanked by two copies of *cHS4*, lowest when




Fig. 2. GFP fluorescence in undifferentiated and differentiated ES cells and in adult hemizygous male and heterozygous female mice. The levels of GFP fluorescence were measured by FACS analysis, and representative histograms are shown. Solid white, black, and gray histograms represent the GFPn, I-GFPn-I, and II-GFPn-II transgenes, respectively. (A) The histograms are from undifferentiated male ES cells grown on feeder layers. (B) Shown is fluorescence of ES cells 4 weeks after they were removed from feeders and allowed to form embryoid bodies with the FACS detector settings identical to those used for undifferentiated ES cells. (C) The histograms are from lymphocytes of male mice hemizygous for the GFPn transgenes. The mean fluorescence \pm standard deviation for three male mice for each transgene are: GFPn, 520 ± 20 ; I-GFPn-I, $1,360 \pm 270$; and II-GFPn-II, $2,630 \pm 610$. (D) Shown is the fluorescence in splenocytes from heterozygous females. The mean fluorescence \pm standard deviation for the GFP⁺ cells are: GFPn, $2,031 \pm 340$ ($n = 4$); I-GFPn-I, $4,076 \pm 644$ ($n = 5$); and II-GFPn-II, $7,511 \pm 576$ ($n = 6$). Note the presence of an approximately equal number of nonfluorescent cells in the females but none in males.

uninsulated, and intermediate when flanked by a single copy of *cHS4* (Fig. 2B). Thus, the flanking insulators block in a copy number-dependent manner the partial repression of the GFPn transgene at the *Hprt* locus that occurs during development.

***cHS4* DNA Insulators Modulate Expression in Adults.** We next determined the effects of flanking insulators on the expression of the transgene when on the Xa in adults. Peripheral WBCs were isolated from transgenic adult males and their GFP fluorescence was determined by FACS analysis. Fig. 2C shows representative histograms of the relative fluorescence in WBCs from transgenic males. When compared with expression from the uninsulated transgene (520 ± 20), expression from the transgene with one flanking copy of the insulators is \approx 2-fold greater ($1,360 \pm 270$) and expression from the transgene with two flanking copies is \approx 4-fold greater ($2,630 \pm 610$). A similar dose effect on the level of fluorescence was seen in GFP⁺ splenocytes from heterozygous X^m/X^p^{I-GFPn-I} and X^m/X^p^{II-GFPn-II} females (Fig. 2D), where X^m is the maternal X chromosome and X^p is the paternal X chromosome. Thus, flanking insulators continue to block repression of the transgene at the *Hprt* locus on the Xa after the completion of development.

We conclude that, because *cHS4* does not have canonical enhancer qualities of its own (8), it acts as a barrier to repression of the transgene at the *Hprt* locus on the Xa during *in vitro* differentiation and in adults and that this barrier function is more effective with two flanking copies than with one. Our experiments clearly demonstrate the dosage effect of *cHS4*'s barrier activity because we have targeted single copies of all of our reporter transgenes (with zero, one, or two flanking copies of *cHS4*) to the same location.




Fig. 3. Expression patterns of paternally and maternally inherited X-linked GFPn transgenes in embryonic day 7.5 embryos. (A–D) z projections of confocal images of the GFP fluorescence signal (pseudocolored yellow) from female embryos dissected at embryonic day 7.5. The dashed line marks the division between emb and extraembryonic (exe) regions of the embryo. (E–H) Single confocal sections of the embryo proper of embryonic day 7.5 females. Embryos were counterstained with TO-PRO-3 to visualize nuclei, which was pseudocolored blue. The merged images are shown, where the combination of yellow and blue produces white. In A–C and E–G, the female embryos are heterozygous for the GFPn, I-GFPn-I, or II-GFPn-II transgene, respectively, which is on their Xp. In D and H, the female embryo is heterozygous for the II-GFPn-II transgene, which is on the Xm. The ectoplacental cone (epc) shows GFP fluorescence only when the transgene is inherited from the mother (D). (Magnifications: A–D, $\times 20$; E–H, $\times 40$.)

CHS4 DNA Insulators Do Not Prevent Random X Inactivation. To analyze the effects of flanking insulators on the expression of the GFPn transgene during X inactivation, males carrying the different GFPn transgenes were bred to WT females. Embryos at 7.5 days postcoitum were then dissected for analysis. This scheme achieved three purposes. First, because only female progeny inherit the GFPn transgene, female embryos could be identified by their fluorescence. Second, because the female embryos also carry a WT X chromosome we could determine the effect of insulators on random X inactivation, which normally inactivates either Xm or Xp in embryonic lineages. Third, because the transgene is paternally inherited, embryos could also be used to examine imprinted X inactivation, which preferentially inactivates the Xp in extraembryonic lineages.

Fig. 3 A–C shows green fluorescent images (pseudocolored yellow) of female embryonic day 7.5 embryos that are heterozygous for a paternally inherited GFPn transgene with zero (X_m/X_p^{GFPn}), one ($X_m/X_p^{I-GFPn-I}$), and two ($X_m/X_p^{II-GFPn-II}$) copies of the flanking insulator. Fig. 3 E–G shows images of the embryonic ectoderm (emb) that merge the GFP fluorescence with TO-PRO-3 fluorescence (pseudocolored blue) used to visualize nuclei. The GFP fluorescence seen in the emb is clearly greater when the transgene is flanked by insulators, confirming the observations in ES cells, WBCs, and splenocytes presented in Fig. 2.

Fig. 3 A and E shows a mosaic pattern of GFP fluorescence in the emb of an X_m/X_p^{GFPn} female, as expected for an X-linked transgene that undergoes random X inactivation in a heterozygous female (27, 28). The same mosaic pattern is seen when the transgene is flanked by one copy of the insulator (Fig. 3 B and F) or two copies (Fig. 3 C and G). The mosaic pattern persists in adults and is unaffected by the presence of the insulators or the parental origin of the transgene as judged by FACS analysis




Fig. 4. Fluorescence *in situ* hybridization for Xist RNA and the II-GFPn-II transgene. Fluorescent images are shown of a GFP⁺ splenocyte (A–C) and GFP[−] splenocyte (D–F) from a female heterozygous for the II-GFPn-II transgene. (A and D) RNA FISH for Xist is shown. The Xist signal (pseudocolored magenta) indicates the Xist RNA coating the Xi. (B and E) DNA FISH for the II-GFPn-II transgene (pseudocolored yellow) is shown. The nucleus is stained with DAPI (blue). (C and F) The merge of the Xist and II-GFPn-II transgene images. Fifty of 50 GFP⁺ splenocytes had the localization pattern shown in C. Twenty-four of 25 GFP[−] splenocytes had the localization pattern shown in F; the 1 of 25 showing the pattern in C probably was caused by contamination with GFP⁺ cells during FACS sorting. (Magnification: $\times 100$.)

from heterozygous females in which approximately half the cells do not fluoresce (Fig. 2D and Tables 1 and 2, which are published as supporting information on the PNAS web site). This finding indicates that flanking insulators do not prevent random X inactivation from silencing of the GFPn transgene on the Xp or Xm.

Although the mosaic pattern of GFP expression seen in the emb is consistent with silencing of the GFPn transgene on the Xi, it does not exclude the possibility that the expressed GFPn transgene is on the Xi and is protected from silencing by the insulators. To test for this possibility, we sorted splenocytes from females heterozygous for the II-GFPn-II transgene into GFP⁺ and GFP[−] populations and performed FISH for the II-GFPn-II transgene and Xist RNA. Fluorescent images in Fig. 4 A–C are of a single nucleus from a GFP⁺ splenocyte. Fig. 4A shows the Xist signal (pseudocolored magenta) that marks the Xi, Fig. 4B shows the II-GFPn-II signal (pseudocolored yellow), and Fig. 4C is the merge. In all GFP⁺ splenocytes in which we have detected both the signal for the transgene and the signal for Xist the two signals are nonoverlapping (Fig. 4C), which demonstrates that the II-GFPn-II transgene is not on the Xi. Overlapping Xist and II-GFPn-II signals, indicating the II-GFPn-II transgene is on the Xi, were observed in the GFP[−] splenocytes (Fig. 4F). These results confirm that flanking CHS4 insulators do not prevent random X inactivation from silencing a transgene at the *Hprt* locus.

CHS4 DNA Insulators Do Not Prevent Imprinted X Inactivation. To test whether insulators prevent imprinted X inactivation, we compared the GFP fluorescence of female embryos that inherited the II-GFPn-II transgene from their father with that of female embryos that inherited the transgene from their mother. Fig. 3 C, D, G, and H show that the emb of the $X_m/X_p^{II-GFPn-II}$ and $X_m^{II-GFPn-II}/X_p$ embryos has essentially indistinguishable mosaic fluorescence, confirming that random X inactivation is not affected by the parent of origin of the transgene. However, in the extra-emb and the ectoplacental cone, fluorescence is

insulators prevent loss of transcriptional activity rather than cause a gain of activity, and that there is an inverse relationship between the protective effects of the flanking insulators on the level of transgene expression and DNA methylation of the transgene promoter.

Although there is generally an inverse correlation between expression and CpG methylation, it is not one to one. The distribution of the expression of cells having the I-GFPn-I transgene is unimodal and approximately midway between that of the GFPn and II-GFPn-II transgenes, but the methylation pattern is bimodal with some of the cells having the S3 CpG site downstream of the β -actin promoter methylated, whereas other cells have the same site unmethylated. We infer that the insulator-induced changes in CpG methylation at this site do not determine expression of the transgene, but the insulator-induced changes in expression determine CpG methylation of the promoter site. This inference is compatible with a model proposed by Felsenfeld and his associates (12, 13) based on their analysis of chromatin modifications associated with a transgene flanked with two copies of cHS4. Our experiments show that two flanking copies of cHS4 are more potent than a single flanking copy in protecting the transgene from repression and its promoter from CpG methylation. We conclude that the more frequently the promoter is active, the more likely it is to escape methylation, but any given cell with intermediate expression can have its promoter methylated or unmethylated.

Conclusions

In summary, we report an investigation of the effects of the cHS4 DNA insulator at a predetermined site on the X chromosome. We have shown that when targeted adjacent to the X-linked *Hprt* locus flanking cHS4 insulators block transgene repression. This block in repression begins during development, persists in adults, and depends on the copy number of flanking cHS4 insulators. We have also shown that flanking cHS4 insulators, containing CTCF binding sites, are not sufficient to form a boundary that allows a transgene to escape X inactivation.

A recent report (24) has identified a sequence element with CTCF binding sites upstream of the X-linked *Jarid1c* gene, which escapes X inactivation but is immediately adjacent to a gene that is inactivated, suggesting that CTCF may play a role in establishing an escape domain boundary. However, our present results demonstrate that flanking cHS4 insulators with CTCF binding sites is not sufficient to establish an X inactivation escape domain at the *Hprt* locus, which implies that escape from X inactivation requires different or additional mechanisms that may be present at the *Jarid1c* escape domain. Given this result, it will be informative to test whether the region at the 5' end of *Jarid1c*, with or without its CTCF binding sites, can cause a transgene to escape X inactivation when targeted to the *Hprt* locus.

Materials and Methods

Gene Targeting and Generation of Transgenic Mice. The GFPn reporter transgene used a *Renilla reniformis* GFPn (Stratagene) and was expressed from a 1.3-kb genomic fragment containing the human β -actin promoter (25). A 1.2-kb fragment containing hypersensitive site 4 (cHS4) from the chicken β -globin locus (8), a gift from G. Felsenfeld (National Institutes of Health, Bethesda), was used as the DNA insulator. The reporter transgenes were cloned into the *Hprt* targeting vector, a modified version of pSKB1 (26). The targeting vectors were linearized with *Pme*I before electroporation. Cell culture, electroporation, selection, and microinjection of ES cells were as described by Bronson *et al.* (26). Southern blot analysis was performed with a random primer-labeled *Rsa*I probe from intron 3 of the mouse *Hprt* gene. The mice were maintained in a facility accredited by the Association for the Assessment and Accreditation of Laboratory

Animal Care International according to Institutional Animal Care and Use Committee-approved guidelines.

In Vitro Differentiation. Undifferentiated ES cells were cultured on γ -irradiated mouse embryonic feeder cells. *In vitro* differentiation of ES cells was performed as described (32). Cells were harvested for FACS analysis by treating them with 0.2% collagenase type IAS (Sigma) for 30 min at 37°C, followed by 0.0125% trypsin-EDTA for 10 min.

FACS Analysis. Undifferentiated and differentiated ES cells and peripheral blood mononuclear cells were analyzed on a Becton Dickinson FACScan analytical flow cytometer. Single-cell suspensions of splenocytes were sorted with a DAKO Modular Flow cytometer. Histograms were processed with DAKO SUMMIT software, version 3.1.

Embryo Dissection and Confocal Microscopy. Transgenic male mice were mated to WT C57BL/6 female mice. Embryos were dissected in PBS and 5% FBS at embryonic day 7.5, examined with a Leica MZLIII stereoscope equipped with a UV lamp and GFP filter, and fixed on ice in PBS and 4% paraformaldehyde for 15–30 min. Embryos were counterstained with TO-PRO-3 (Molecular Probes) as described (33). Images were acquired the same day with a Zeiss LSM5 Pascal confocal laser scanning microscope. The dynamic range was set by using the range palette function, and the photomultiplier gain settings were 980, 967, and 902 for embryos with the GFPn, I-GFPn-I, and II-GFPn-II transgenes, respectively. For each embryo, 35–60 optical sections at 2.2 μ m were captured with a Zeiss 20/NA 0.75 objective. The stacks of optical sections were processed into a single z projection by using IMAGEJ software. Single optical sections were captured at $\times 40$ with a Zeiss 40/NA 1.2 objective. The 8-bit grayscale images were pseudocolored with IMAGEJ software, adjusted with the same values, and merged in Adobe Systems (San Jose, CA) PHOTOSHOP, version 7.0.1.

FISH. Splens from heterozygous female adult GFPn transgenic mice were dissociated into single-cell suspensions in RPMI medium 1640, 0.1% BSA (NEB, Beverly, MA), and 10 units/ml RNasin (Promega). Splenocytes were then sorted into GFP⁺ and GFP⁻ populations with the DAKO Modular Flow cytometer. The cells were spun onto slides by using a Shandon (Pittsburgh) Cytospin at 112 \times g for 5 min. DNA and RNA FISH was performed as described (34). The probes were generated by random priming by using the BioPrime DNA Labeling System (Invitrogen) and Cy3-dCTP (Amersham Pharmacia) for the 7-kb II-GFPn-II probe and FITC-dUTP (Roche) for the Xist exon 6 probe. Fluorescent images were captured with a Leica (Deerfield, IL) DML fluorescence microscope and SPOT RT software. The 8-bit grayscale images were pseudocolored with IMAGEJ software, adjusted, and merged in Adobe PHOTOSHOP 7.0.1.

DNA Methylation Analysis. Splenocytes from heterozygous female adult GFPn transgenic mice were sorted into GFP⁺ and GFP⁻ populations by using the DAKO Modular Flow cytometer. DNA from $\approx 3 \times 10^6$ GFP⁺ and 3×10^6 GFP⁻ cells from the three GFPn transgenic lines was digested with *Eco*RI (NEB). One-third of the *Eco*RI-digested DNA was digested with *Sma*I (NEB), and one-third was digested with *Xma*I (NEB). Digested DNA was analyzed by Southern blot with the GFPn coding sequence as a probe. Intensity of the hybridized bands was quantified by using IMAGEJ software.

We thank members of the University of North Carolina Animal Models Laboratory, the University of North Carolina Flow Cytometry Facility, and the Microscopy Services Laboratory for assistance; Gary Felsenfeld

for the pJC-HS4 plasmid containing the cHS4 insulator; and Robert Bagnell, Colyn Crane-Robinson, Nobuyo Maeda, Nathan Montgomery,

Kumar Pandya, and Barbara Panning for help and advice. This work was supported by National Institutes of Health Grant HL37001.

1. Weiler, K. S. & Wakimoto, B. T. (1995) *Annu. Rev. Genet.* **29**, 577–605.
2. Muller, H. (1930) *J. Genet.* **22**, 299–335.
3. Kellum, R. & Schedl, P. (1991) *Cell* **64**, 941–950.
4. Burgess-Beusse, B., Farrell, C., Gaszner, M., Litt, M., Mutskov, V., Recillas-Targa, F., Simpson, M., West, A. & Felsenfeld, G. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 16433–16437.
5. West, A. G., Gaszner, M. & Felsenfeld, G. (2002) *Genes Dev.* **16**, 271–288.
6. Saitoh, N., Bell, A. C., Recillas-Targa, F., West, A. G., Simpson, M., Pikaart, M. & Felsenfeld, G. (2000) *EMBO J.* **19**, 2315–2322.
7. Hebbes, T. R., Clayton, A. L., Thorne, A. W. & Crane-Robinson, C. (1994) *EMBO J.* **13**, 1823–1830.
8. Chung, J. H., Whiteley, M. & Felsenfeld, G. (1993) *Cell* **74**, 505–514.
9. Bell, A. C., West, A. G. & Felsenfeld, G. (1999) *Cell* **98**, 387–396.
10. Recillas-Targa, F., Pikaart, M. J., Burgess-Beusse, B., Bell, A. C., Litt, M. D., West, A. G., Gaszner, M. & Felsenfeld, G. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 6883–6888.
11. Pikaart, M. J., Recillas-Targa, F. & Felsenfeld, G. (1998) *Genes Dev.* **12**, 2852–2862.
12. West, A. G., Huang, S., Gaszner, M., Litt, M. D. & Felsenfeld, G. (2004) *Mol. Cell* **16**, 453–463.
13. Mutskov, V. J., Farrell, C. M., Wade, P. A., Wolffe, A. P. & Felsenfeld, G. (2002) *Genes Dev.* **16**, 1540–1554.
14. Heard, E. (2005) *Curr. Opin. Genet. Dev.* **15**, 482–489.
15. Lyon, M. F. (1961) *Nature* **190**, 372–373.
16. Cohen, D. E. & Lee, J. T. (2002) *Curr. Opin. Genet. Dev.* **12**, 219–224.
17. Carrel, L., Cottle, A. A., Goglin, K. C. & Willard, H. F. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 14440–14444.
18. Brown, C. J. & Grealley, J. M. (2003) *Trends Genet.* **19**, 432–438.
19. Disteché, C. M. (1995) *Trends Genet.* **11**, 17–22.
20. Tsuchiya, K. D. & Willard, H. F. (2000) *Mamm. Genome* **11**, 849–854.
21. Goldman, M. A., Stokes, K. R., Idzerda, R. L., McKnight, G. S., Hammer, R. E., Brinster, R. L. & Gartler, S. M. (1987) *Science* **236**, 593–595.
22. Whyatt, D., Lindeboom, F., Karis, A., Ferreira, R., Milot, E., Hendriks, R., de Bruijn, M., Langeveld, A., Gribnau, J., Grosveld, F. & Philipsen, S. (2000) *Nature* **406**, 519–524.
23. Chong, S., Kontaraki, J., Bonifer, C. & Riggs, A. D. (2002) *Mol. Cell. Biol.* **22**, 4667–4676.
24. Filippova, G. N., Cheng, M. K., Moore, J. M., Truong, J. P., Hu, Y. J., Nguyen, D. K., Tsuchiya, K. D. & Disteché, C. M. (2005) *Dev. Cell* **8**, 31–42.
25. Sugiyama, H., Niwa, H., Makino, K. & Kakunaga, T. (1988) *Gene* **65**, 135–139.
26. Bronson, S. K., Plaehn, E. G., Kluckman, K. D., Hagaman, J. R., Maeda, N. & Smithies, O. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 9067–9072.
27. Hadjantonakis, A. K., Cox, L. L., Tam, P. P. & Nagy, A. (2001) *Genesis* **29**, 133–140.
28. Wang, J., Mager, J., Chen, Y., Schneider, E., Cross, J. C., Nagy, A. & Magnuson, T. (2001) *Nat. Genet.* **28**, 371–375.
29. Bird, A. (2002) *Genes Dev.* **16**, 6–21.
30. Migeon, B. R. (1994) *Trends Genet.* **10**, 230–235.
31. Weber, M., Davies, J. J., Wittig, D., Oakeley, E. J., Haase, M., Lam, W. L. & Schubeler, D. (2005) *Nat. Genet.* **37**, 853–862.
32. Wobus, A. M., Wallukat, G. & Hescheler, J. (1991) *Differentiation* **48**, 173–182.
33. Schejter, E. D. & Wieschaus, E. (1993) *Cell* **75**, 373–385.
34. Panning, B., Dausman, J. & Jaenisch, R. (1997) *Cell* **90**, 907–916.